Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)

Next Previous
Trial Profile

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vidofludimus calcium (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms EMPhASIS
  • Sponsors Immunic

Most Recent Events

  • 30 Apr 2024 According to an Immunic media release, the Extended results from the pooled data of cohorts 1 and 2 in this trial has been published on April 25, 2024 in Neurology Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology.
  • 30 Apr 2024 Results published in the Immunic Inc Media Release
  • 13 Oct 2023 Results of an analysis reporting safety and efficacy data and confirming 30 and 45mg doses as appropriate for Phase 3 evaluation in MS presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top